Under the Proposed Regulations, modifications of a
Stock Right to achieve the following results generally are not considered modifications that result in a new grant:
In a regulatory filing, the bank said that it has completed a PHP32bn
stock rights offer with existing shareholders.
Correction can be made to outstanding
stock rights even if other rights in the same grant were already exercised and are therefore ineligible for correction.
An additional signatory to the
Stock Rights Agreement was Mrs.
Poison pills" are contingent
stock rights that are incorporated into a stock certificate or distributed as a dividend, which serve to enable a corporation to defend itself against an unsolicited tender offer.
El Capitan's Board of Directors believes that retaining in place anti-takeover protection, in the form of a new preferred
stock rights plan, will reduce the likelihood that any person or group would gain control of the Company by open market accumulation or other coercive takeover tactics without paying a control premium for all shares.
the Rights Agent, amending its Preferred
Stock Rights Agreement to accelerate the "Final Expiration Date" under the Rights Agreement to May 25, 2007, and terminate the Preferred Stock Purchase Rights governed by the Rights Agreement on that date.
Reasonable valuation method: Notice 2006-4 (5) addresses concerns that, although
stock rights may have been intended to be granted at FMV, the issuers may not be able to demonstrate that the exercise price was determined using a reasonable valuation method in accordance with Notice 2005-1 or the proposed regulations.
333-160231) and intends to file a prospectus supplement with respect to the proposed common
stock rights offering.
6 Billion profits of its
stock rights offering previous year.
7m common
stock rights offering, including the purchase of unsubscribed shares by it new investors, which expired on May 21, 2012.
Includes
stock rights in which a corporation either reported (or reasonably expects to report) a financial expense due to the issuance of a
stock right with an exercise price lower than the fair market value of the underlying stock at the grant date that was not timely reported on financial statements or reports for the period.
